A Phase III clinical trial that included patients with advanced NSCLC demonstrated a significant improvement in progression-free survival (PFS) and a considerable intracranial disease response in individuals treated with selpercatinib compared to those receiving chemotherapy [9]. However, real-world data on long-term outcomes of selpercatinib in patients with RET fusion-positive NSCLC and symptomatic central nervous system (CNS) metastases remain limited. The gene discussed is RET; the disease is non-small cell lung carcinoma.